Rat Anti-Mouse Lyve-1
Slide this table
|Reconstitution||Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.|
|Stability and Storage||Lyophilized samples are stable for 2 years from date of receipt when stored at -70°C. Reconstituted antibody can be aliquoted and stored frozen at < -20 °C for at least for six months without detectable loss of activity.|
|Preparation||Produced from a hybridoma fused by a mouse myeloma with B cells obtained from a rat immunized with mouse LYVE-1 recombinant protein. IgG2 fraction of the culture supernatant was purified by Protein G affinity chromatography.|
|Antigen||Mouse recombinant LYVE-1|
|Application||WB, IHC (F)|
|Synonyms||Lyve1; Xlkd1; Lyve-1; Crsbp-1; 1200012G08Rik|
|Description||LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.|
- A Distinct Role of the Autonomic Nervous System in Modulating the Function of Lymphatic Vessels under Physiological and Tumor-Draining Conditions. S. B. Bachmann et al., Cell Rep. 2019 Jun 11; 27(11): 3305–3314.e13.
- Mechanisms of Tumor-Induced Lymphovascular Niche Formation in Draining Lymph Nodes. Commerford CD et al., Cell Rep. 2018 Dec 26;25(13):3554-3563.e4.
- An Adaptor Molecule Afadin Regulates Lymphangiogenesis by Modulating RhoA Activity in the Developing Mouse Embryo. T. Majima et al., PLoS One. 2013; 8(6): e68134.
- Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. S. M. Zeisberger et al., Br J Cancer. 2006 Aug 7; 95(3): 272–281.
All prices plus VAT + possible delivery charges